GSK Belgium, VNVC sign MoU on strategic cooperation
VOV.VN - GlaxoSmithKline S.A. of Belgium, a global leading pharmaceutical company, and Vietnam Vaccine Joint Stock Company (VNVC) signed a memorandum of understanding in Ho Chi Minh City on May 11, opening up opportunities for Vietnam to have more new vaccines.
Under the signed document, both sides have agreed to establish a sustainable vaccine supply chain, expand vaccine coverage to all citizens, and raise public awareness about the role of vaccines in protecting human health.
The MoU was signed during the launch of GSK Pharma Vietnam Company Limited.
Addressing the signing ceremony, Pham Thi My Lien, chairwoman of GSK Pharma Vietnam Co. Ltd. affirmed that GSK would make a greater effort to bring new vaccines to Vietnam in the coming time.
“As GSK is a leading vaccine manufacturer, we are passionate about protecting Vietnamese people at all stages of life,” said the executive.
According to Vu Thi Thu Ha, a VNVC official, the COVID-19 pandemic has had a great impact on the global supply chain for more than two years. However, GSK has still supplied enough vaccines to VNVC in a timely manner to help millions of children and adults prevent dangerous infectious diseases.
This is the second time VNVC and GSK have signed a cooperation document, following the first such agreement inked in 2019.
Besides GSK, VNVC has also signed a comprehensive strategic cooperation agreement with Sanofi S.A. of France. It is also an important partner of many leading pharmaceutical companies in the world such as AstraZeneca, Pfizer, and MSD.